The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke
Dyslipidemia is a major modifiable risk factor for ischemic stroke. Treatment with statins reduces the incidence of recurrent ischemic stroke and also reduces coronary events in patients with a history of ischemic stroke. Therefore, statins represent an important component of secondary prevention of...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Diseases |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-9721/10/1/3 |
| _version_ | 1797471983666987008 |
|---|---|
| author | Alexandra Tsankof Konstantinos Tziomalos |
| author_facet | Alexandra Tsankof Konstantinos Tziomalos |
| author_sort | Alexandra Tsankof |
| collection | DOAJ |
| description | Dyslipidemia is a major modifiable risk factor for ischemic stroke. Treatment with statins reduces the incidence of recurrent ischemic stroke and also reduces coronary events in patients with a history of ischemic stroke. Therefore, statins represent an important component of secondary prevention of ischemic stroke. In patients who do not achieve low-density lipoprotein cholesterol (LDL-C) targets despite treatment with the maximal tolerated dose of a potent statin, ezetimibe should be added to their lipid-lowering treatment and also appears to reduce the risk of cardiovascular events. Selected patients who do not achieve LDL-C targets despite statin/ezetimibe combination are candidates for receiving proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Finally, it appears that adding icosapent ethyl might also reduce cardiovascular morbidity in patients who have achieved LDL-C targets but have persistently elevated triglyceride levels. |
| first_indexed | 2024-03-09T19:55:48Z |
| format | Article |
| id | doaj.art-3248776c136847bbaed1ef82881c2a32 |
| institution | Directory Open Access Journal |
| issn | 2079-9721 |
| language | English |
| last_indexed | 2024-03-09T19:55:48Z |
| publishDate | 2021-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diseases |
| spelling | doaj.art-3248776c136847bbaed1ef82881c2a322023-11-24T00:56:42ZengMDPI AGDiseases2079-97212021-12-01101310.3390/diseases10010003The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic StrokeAlexandra Tsankof0Konstantinos Tziomalos1First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, GreeceFirst Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, GreeceDyslipidemia is a major modifiable risk factor for ischemic stroke. Treatment with statins reduces the incidence of recurrent ischemic stroke and also reduces coronary events in patients with a history of ischemic stroke. Therefore, statins represent an important component of secondary prevention of ischemic stroke. In patients who do not achieve low-density lipoprotein cholesterol (LDL-C) targets despite treatment with the maximal tolerated dose of a potent statin, ezetimibe should be added to their lipid-lowering treatment and also appears to reduce the risk of cardiovascular events. Selected patients who do not achieve LDL-C targets despite statin/ezetimibe combination are candidates for receiving proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Finally, it appears that adding icosapent ethyl might also reduce cardiovascular morbidity in patients who have achieved LDL-C targets but have persistently elevated triglyceride levels.https://www.mdpi.com/2079-9721/10/1/3ischemic strokesecondary preventionlipidsstatinsezetimibeproprotein convertase subtilisin/kexin type 9 inhibitors |
| spellingShingle | Alexandra Tsankof Konstantinos Tziomalos The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke Diseases ischemic stroke secondary prevention lipids statins ezetimibe proprotein convertase subtilisin/kexin type 9 inhibitors |
| title | The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke |
| title_full | The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke |
| title_fullStr | The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke |
| title_full_unstemmed | The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke |
| title_short | The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke |
| title_sort | role of lipid lowering treatment in the secondary prevention of ischemic stroke |
| topic | ischemic stroke secondary prevention lipids statins ezetimibe proprotein convertase subtilisin/kexin type 9 inhibitors |
| url | https://www.mdpi.com/2079-9721/10/1/3 |
| work_keys_str_mv | AT alexandratsankof theroleoflipidloweringtreatmentinthesecondarypreventionofischemicstroke AT konstantinostziomalos theroleoflipidloweringtreatmentinthesecondarypreventionofischemicstroke AT alexandratsankof roleoflipidloweringtreatmentinthesecondarypreventionofischemicstroke AT konstantinostziomalos roleoflipidloweringtreatmentinthesecondarypreventionofischemicstroke |